Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
HESTER BIOSCIENCES ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
HESTER BIOSCIENCES Mar-23 |
ADCOCK INGRAM Jun-14 |
HESTER BIOSCIENCES/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 2,852 | 321 | - | |
Low | Rs | 1,416 | 232 | - | |
Sales per share (Unadj.) | Rs | 312.7 | 95.5 | - | |
Earnings per share (Unadj.) | Rs | 32.9 | -24.1 | - | |
Cash flow per share (Unadj.) | Rs | 57.3 | -20.0 | - | |
Dividends per share (Unadj.) | Rs | 8.00 | 0 | - | |
Avg Dividend yield | % | 0.4 | 0 | - | |
Book value per share (Unadj.) | Rs | 328.7 | 75.0 | - | |
Shares outstanding (eoy) | m | 8.51 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.8 | 2.9 | 235.8% | |
Avg P/E ratio | x | 64.7 | -11.5 | -563.9% | |
P/CF ratio (eoy) | x | 37.3 | -13.9 | -268.8% | |
Price / Book Value ratio | x | 6.5 | 3.7 | 176.0% | |
Dividend payout | % | 24.3 | 0 | - | |
Avg Mkt Cap | Rs m | 18,152 | 46,656 | 38.9% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 560 | 2,928 | 19.1% | |
Avg. sales/employee | Rs Th | 0 | 3,756.2 | - | |
Avg. wages/employee | Rs Th | 0 | 682.1 | - | |
Avg. net profit/employee | Rs Th | 0 | -946.5 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 2,661 | 16,125 | 16.5% | |
Other income | Rs m | 154 | 113 | 136.0% | |
Total revenues | Rs m | 2,814 | 16,238 | 17.3% | |
Gross profit | Rs m | 548 | -2,794 | -19.6% | |
Depreciation | Rs m | 207 | 696 | 29.7% | |
Interest | Rs m | 93 | 437 | 21.3% | |
Profit before tax | Rs m | 402 | -3,814 | -10.5% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 121 | 238 | 50.8% | |
Profit after tax | Rs m | 280 | -4,063 | -6.9% | |
Gross profit margin | % | 20.6 | -17.3 | -118.9% | |
Effective tax rate | % | 30.2 | -6.2 | -483.0% | |
Net profit margin | % | 10.5 | -25.2 | -41.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 2,276 | 11,810 | 19.3% | |
Current liabilities | Rs m | 1,487 | 6,645 | 22.4% | |
Net working cap to sales | % | 29.7 | 32.0 | 92.6% | |
Current ratio | x | 1.5 | 1.8 | 86.1% | |
Inventory Days | Days | 47 | 111 | 42.5% | |
Debtors Days | Days | 109 | 124 | 88.1% | |
Net fixed assets | Rs m | 4,424 | 6,884 | 64.3% | |
Share capital | Rs m | 85 | 75 | 113.6% | |
Net worth | Rs m | 2,797 | 12,657 | 22.1% | |
Long term debt | Rs m | 1,849 | 4,448 | 41.6% | |
Total assets | Rs m | 6,700 | 23,909 | 28.0% | |
Interest coverage | x | 5.3 | -7.7 | -68.7% | |
Debt to equity ratio | x | 0.7 | 0.4 | 188.0% | |
Sales to assets ratio | x | 0.4 | 0.7 | 58.9% | |
Return on assets | % | 5.6 | -15.2 | -36.8% | |
Return on equity | % | 10.0 | -32.1 | -31.2% | |
Return on capital | % | 10.6 | -19.8 | -53.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 236 | 1,376 | 17.1% | |
From Investments | Rs m | -770 | -423 | 182.2% | |
From Financial Activity | Rs m | 418 | 4,037 | 10.3% | |
Net Cashflow | Rs m | -116 | 4,990 | -2.3% |
Compare HESTER BIOSCIENCES With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare HESTER BIOSCIENCES With: PROCTER & GAMBLE HEALTH BAFNA PHARMA SEQUENT SCIENTIFIC CIAN HEALTHCARE ISHITA DRUGS
Indian share markets continued the momentum as the session progressed and ended on firm footing.